trial
as of 2026-07-01Ketogenic Metabolic Therapy in Schizophrenia, Bipolar Disorder, Major Depressive Disorder: Deep Omic Profiling
NCTId NCT06748950
at a glance
— · Not Yet Recruiting
Enrollment 120 (estimated)
Sponsored by Stanford University
Primary completion 2028-07
Synthesized from structured facts only — each point cited above.
Design & status
Phase
—
Status
Not Yet Recruiting
Enrollment
120 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2025-07
Primary completion
2028-07
Eligibility
ALL · 18 Years · 80 Years
Interventions & indications
Sponsors
Stanford UniversityLead Sponsor
Investigators
2
Shebani Sethi, MD, ABOMPrincipal Investigator
Michael Snyder, PhDPrincipal Investigator
Sites
1 total
Palo Alto, United States
Facts & assertions
4 sourced
Enrollment
120
Phase
NA
Primary Completion Date
2028-07
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
lead_sponsor
company
indication
investigator
person
person